Archive | BIOTRONIK

BIOTRONIK - Archive

2022
August
31,
2022
| 18:52 PM Europe/Amsterdam
United States, August 30, 2022 – BIOTRONIK’s LiveSupport feature has been successfully used to remotely support Cardiac Rhythm Management (CRM) clinics. This new technology enables BIOTRONIK representatives to provide programmer support from remote l...
Read more
July
26,
2022
| 17:00 PM Europe/Amsterdam
LAKE OSWEGO, Ore., July 26, 2022 - BIOTRONIK, LAKE OSWEGO, USA , announced that it received U.S. Food and Drug Administration (FDA) approval of its innovative Pulsar®-18 T3 peripheral self-expanding stent system for an improved implantation procedure...
Read more
July
22,
2022
| 18:45 PM Europe/Amsterdam
LAKE OSWEGO, OR, July 22, 2022 – BIOTRONIK, Inc. announced today that it has entered into a civil settlement with the U.S. Department of Justice, the U.S. Attorney's Office for the Central District of California, and the U.S. Department of Health and...
Read more
July
06,
2022
| 12:50 PM Europe/Amsterdam
United States, July 6, 2022 – BIOTRONIK’s state-of-the-art LiveSupport feature was used to remotely support two BIOMONITOR Implantable Cardiac Monitor (ICM) implants shortly after launch. Both procedures were performed with a BIOTRONIK representative...
Read more
April
26,
2022
| 16:00 PM Europe/Amsterdam
LAKE OSWEGO, Oregon - April 26, 2022 - BIOTRONIK, Inc. announced today it has received U.S. Food and Drug Administration (FDA) approval of Renamic Neo, the company’s state-of-the-art programmer for implanted cardiac rhythm management devices such as ...
Read more
April
04,
2022
| 19:35 PM Europe/Amsterdam
WASHINGTON, United States, April 4, 2022 – In conjunction with BIOTRONIK, Valentina Kutyifa, MD, PhD, presented the first interim analysis results from the BIO-LIBRA study in a poster contribution at the American College of Cardiology’s 71st Annual S...
Read more
February
28,
2022
| 15:00 PM Europe/Amsterdam
BÜLACH, Switzerland, February 28, 2022 – BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial, which was presented yesterday at the 2022 CRT Conference during a late-breaking clinical trial session by Dr. David Kandzari, US Princi...
Read more
2021
December
22,
2021
| 00:00 AM Europe/Amsterdam
The discovery of a high-severity vulnerability known as Log4Shell Log4Shell (CVE-2021-44228, CVSSv3 10.0) was disclosed publicly on December 9, 2021, while a related lower-severity vulnerability (CVE-2021-45046, CVSSv3 9.0), (CVE-2021-45105, CVSSv3 7...
Read more
September
29,
2021
| 15:00 PM Europe/Amsterdam
LAKE OSWEGO, Oregon - BIOTRONIK announced today it received U.S. Food and Drug Administration (FDA) approval of its Orsiro® Mission bioabsorbable polymer drug-eluting stent system (BP-DES). The company also announced the first U.S. implant and full c...
Read more
September
09,
2021
| 15:00 PM Europe/Amsterdam
LAKE OSWEGO, Oregon—Following the European Society of Cardiology (ESC) Congress 2021, BIOTRONIK today announced the first observational results of the CERTITUDE registry. The registry is designed to evaluate real-world clinical outcomes of patients i...
Read more
August
18,
2021
| 15:30 PM Europe/Amsterdam
BIOTRONIK today announced the results from a new study published in EUROPACE this week confirming that heart failure (HF) decompensation can be predicted early when monitored using an algorithm that combines existing remote monitoring trends and base...
Read more
July
30,
2021
| 13:00 PM Europe/Amsterdam
In association with Heart Rhythm 2021, BIOTRONIK today announced first enrollments in the landmark BIO-AffectDX trial, designed to evaluate clinical outcomes of cardiac resynchronization therapy (CRT) in patients with heart failure (HF) and atrial fi...
Read more
July
28,
2021
| 12:24 PM Europe/Amsterdam
In association with Heart Rhythm 2021, BIOTRONIK today announced that the latest implantable cardiac monitor (ICM), BIOMONITOR IIIm, has been recognized by internationally-renowned research analysts Frost & Sullivan as high-performing across a range ...
Read more
January
13,
2021
| 18:29 PM Europe/Amsterdam
BIOTRONIK announced today that more cardiac patients will have immediate access to its exclusive Vital Data Sensor technology. In an unprecedented move, BIOTRONIK will extend the technology available in its latest generation of injectable cardiac mon...
Read more
2020
December
16,
2020
| 16:00 PM Europe/Amsterdam
BIOTRONIK today announced FDA clearance and availability of the Vital Data Sensor, which identifies body temperature increases potentially associated with fever, in the new BIOMONITOR IIIm injectable cardiac monitor (ICM), as shown in a published cas...
Read more
June
19,
2020
| 20:50 PM Europe/Amsterdam
CardioMessenger devices form an essential part of BIOTRONIK’s remote monitoring system, enabling the secure transmission of critical patient and device data to the treating physician. As the company that pioneered remote monitoring, we have taken cyb...
Read more
June
01,
2020
| 16:00 PM Europe/Amsterdam
BIOTRONIK today announced that it has received a group purchasing contract from Vizient, Inc., the largest, member-driven, healthcare performance improvement company in the United States. The contract increases access to BIOTRONIK’s proven, trusted v...
Read more
May
27,
2020
| 18:50 PM Europe/Amsterdam
Results recently published in the Journal of Cardiovascular Electrophysiology confirm that BIOTRONIK's unique two-lead CRT-DX system provides equivalent therapy to more conventional three-lead systems. CRT-DX systems consist of a CRT-DX pulse generat...
Read more
April
01,
2020
| 21:27 PM Europe/Amsterdam
As the COVID-19 pandemic continues, we are conscious of the enormous strain that you are all under. We share your concerns about the spread of the virus and the disruption it is causing globally. We are doing what we can to help minimize this disrupt...
Read more
February
24,
2020
| 13:48 PM Europe/Amsterdam
BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented yesterday at the 2020 CRT Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinfo...
Read more
January
27,
2020
| 13:41 PM Europe/Amsterdam
BIOTRONIK, Inc. today announced the appointment of David Hayes, MD, FACC, as Chief Medical Officer. Dr. Hayes will oversee the development of BIOTRONIK’s cardiovascular solutions with a focus on advancing unique, proven innovations that help physicia...
Read more
2019
July
31,
2019
| 13:58 PM Europe/Amsterdam
BIOTRONIK today announced the company’s PK Papyrus® covered coronary stent system1 has been named a finalist in the 2019 Prix Galien USA Awards Ceremony for Best Medical Technology.PK Papyrus is used in emergency situations to create a physical barri...
Read more
July
22,
2019
| 13:35 PM Europe/Amsterdam
BIOTRONIK today announced the publication of the SENSE Trial results in the Journal of Cardiac Electrophysiology, proving BIOTRONIK’s DX system is equivalent to dual-chamber implantable cardioverter defibrillators (ICDs) in detecting atrial high-rate...
Read more
July
08,
2019
| 13:48 PM Europe/Amsterdam
BIOTRONIK today announced FDA clearance of the BIOMONITOR III injectable cardiac monitor (ICM). BIOMONITOR III is designed to document suspected arrhythmia or unexplained syncope with increased clarity, enabling fast diagnosis and appropriate treatme...
Read more
May
06,
2019
| 13:53 PM Europe/Amsterdam
BIOTRONIK today announced initial enrollment into the BIO-LIBRA study, a first-of-its kind, large-scale prospective study to analyze sex-specific outcomes in patients with non-ischemic cardiomyopathy (NICM) treated with cardiac defibrillator device t...
Read more
April
29,
2019
| 14:02 PM Europe/Amsterdam
BIOTRONIK today announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices. Leading electrophysiologists throughout the United States are now treating patients with the new implantable cardioverter defi...
Read more
April
10,
2019
| 14:05 PM Europe/Amsterdam
BIOTRONIK today announced the United States (US) commercial launch of the PK Papyrus® covered coronary stent system for use in the emergency treatment of acute coronary perforations.1,2 More than 800,000 percutaneous coronary intervention procedur...
Read more
March
14,
2019
| 14:11 PM Europe/Amsterdam
BIOTRONIK today announced FDA approval of the Acticor and Rivacor high-voltage cardiac rhythm management (CRM) device families for treatment of patients with cardiac arrhythmias. The six new tachycardia solutions include Rivacor VR-T, Rivacor DR-T, R...
Read more
February
25,
2019
| 14:44 PM Europe/Amsterdam
BIOTRONIK today announced FDA approval of the Orsiro drug-eluting stent (DES) system. Orsiro is the first and only ultrathin DES to outperform the clinical standard, Xience.1,2 Orsiro received CE marking in 2011 and has been used to treat more than o...
Read more
2018
September
24,
2018
| 19:25 PM Europe/Amsterdam
Today, BIOTRONIK announced two-year data from the BIOFLOW-V randomized trial comparing the Orsiro and Xience1 drug-eluting stents (DES). The data shows statistically improved outcomes for patients treated with Orsiro across a range of clinical endpoi...
Read more